Macitentan Phase III PAH outcome study results to be presented at CHEST 2012

ALLSCHWIL/BASEL, SWITZERLAND – 10 September 2012 – Actelion (SIX: ATLN) today announced that the results from the first ever Phase III long-term outcome study with macitentan in patients with Pulmonary …